地尔硫和单硝酸异山梨酯联合治疗不稳定性心绞痛的疗效观察被引量：6

下载PDF

导出

摘要目的观察地尔硫片和单硝酸异山梨酯缓释片联合应用治疗不稳定性心绞痛的临床疗效。方法将64例门诊和住院的不稳定心绞痛患者随机分为对照组、治疗组两组,各32例;对照组在降脂、抗血小板聚集等治疗基础上,口服地尔硫片;治疗组在对照组的基础上,口服单硝酸异山梨酯缓释片。疗程均为6周。比较治疗前后心绞痛发作频次、持续时间、心绞痛发作时分级、心电图缺血性改变、心率、血压变化,观测血尿常规、肝肾功能等安全指标。结果两组治疗后心绞痛发作频次、持续时间均明显减少,与治疗前相比,差异均有显著统计学意义(P<0.01);治疗组与对照组治疗后比较,差异有统计学意义(P<0.05);心绞痛分级两组治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.05或P<0.01);对照组治疗后心率较治疗前下降,差异具有显著统计学意义(P<0.01),血压较治疗前亦降低,差异具有统计学意义(P<0.05);治疗组治疗后心率与治疗前比较,差异无明显统计学意义(P>0.05),治疗后血压与治疗前相比,差异均有显著统计学意义(P<0.01),与对照组治疗后比较,差异有统计学意义(P<0.05)。两组患者治疗前后血尿常规、肝肾功能无明显变化。结论联合口服地尔硫和单硝酸异山梨酯治疗不稳定性心绞痛效果显著,无明显不良反应,值得推广。

作者吴金灿

机构地区浙江省浦江县中医院ICU科

出处《中国现代医生》 2010年第36期32-33,共2页 China Modern Doctor

关键词地尔硫单硝酸异山梨酯不稳定性心绞痛

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量：2696
2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量：2149

二级参考文献24

1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量：194
2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.